AQR Capital Management LLC Grows Stock Holdings in Glaukos Co. (NYSE:GKOS)

AQR Capital Management LLC lifted its position in Glaukos Co. (NYSE:GKOS) by 5.4% in the second quarter, Holdings Channel.com reports. The firm owned 4,141 shares of the medical instruments supplier’s stock after purchasing an additional 211 shares during the quarter. AQR Capital Management LLC’s holdings in Glaukos were worth $490,000 at the end of the most recent reporting period.

Several other institutional investors have also recently modified their holdings of GKOS. GAMMA Investing LLC lifted its stake in shares of Glaukos by 68.8% in the 2nd quarter. GAMMA Investing LLC now owns 1,192 shares of the medical instruments supplier’s stock valued at $141,000 after acquiring an additional 486 shares during the last quarter. Caldwell Sutter Capital Inc. lifted its position in Glaukos by 5,860.0% in the first quarter. Caldwell Sutter Capital Inc. now owns 1,490 shares of the medical instruments supplier’s stock valued at $140,000 after purchasing an additional 1,465 shares during the last quarter. Fifth Third Wealth Advisors LLC purchased a new stake in shares of Glaukos during the second quarter valued at approximately $187,000. Brighton Jones LLC bought a new position in shares of Glaukos in the second quarter worth approximately $208,000. Finally, Mount Yale Investment Advisors LLC purchased a new position in shares of Glaukos in the second quarter worth $212,000. 99.04% of the stock is currently owned by institutional investors.

Glaukos Stock Performance

Shares of GKOS stock opened at $130.14 on Tuesday. The company’s fifty day moving average price is $127.44 and its 200-day moving average price is $116.23. The stock has a market cap of $6.55 billion, a PE ratio of -45.19 and a beta of 1.02. The company has a current ratio of 5.48, a quick ratio of 4.67 and a debt-to-equity ratio of 0.19. Glaukos Co. has a 12 month low of $59.22 and a 12 month high of $136.60.

Glaukos (NYSE:GKOS) last announced its quarterly earnings data on Wednesday, July 31st. The medical instruments supplier reported ($0.52) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.52). Glaukos had a negative net margin of 47.39% and a negative return on equity of 22.51%. The business had revenue of $95.70 million for the quarter, compared to analysts’ expectations of $88.86 million. During the same quarter in the prior year, the company earned ($0.55) earnings per share. The business’s revenue was up 19.0% compared to the same quarter last year. On average, equities analysts expect that Glaukos Co. will post -2.18 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have issued reports on GKOS shares. Truist Financial raised their price target on shares of Glaukos from $145.00 to $152.00 and gave the stock a “buy” rating in a report on Monday. Piper Sandler upped their price target on Glaukos from $110.00 to $140.00 and gave the company an “overweight” rating in a research report on Thursday, August 1st. BTIG Research increased their price objective on Glaukos from $131.00 to $139.00 and gave the stock a “buy” rating in a report on Wednesday, August 28th. Wells Fargo & Company upped their target price on Glaukos from $120.00 to $135.00 and gave the company an “overweight” rating in a report on Thursday, August 1st. Finally, Morgan Stanley raised their price target on Glaukos from $100.00 to $120.00 and gave the stock an “equal weight” rating in a research note on Monday, July 15th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $130.45.

Insider Buying and Selling

In other news, Director Marc Stapley sold 6,250 shares of Glaukos stock in a transaction dated Thursday, August 15th. The stock was sold at an average price of $125.93, for a total value of $787,062.50. Following the completion of the transaction, the director now owns 34,076 shares of the company’s stock, valued at $4,291,190.68. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, Director Gilbert H. Kliman sold 3,000 shares of the business’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $130.67, for a total value of $392,010.00. Following the completion of the transaction, the director now owns 32,336 shares in the company, valued at $4,225,345.12. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Marc Stapley sold 6,250 shares of the company’s stock in a transaction on Thursday, August 15th. The shares were sold at an average price of $125.93, for a total value of $787,062.50. Following the transaction, the director now directly owns 34,076 shares in the company, valued at approximately $4,291,190.68. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 39,250 shares of company stock worth $4,825,873 in the last 90 days. Insiders own 6.40% of the company’s stock.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.